source
- BMS leverages Celgene merger to revive neuroscience pipeline amid delayed readoutsBristol Myers Squibb, long recognized for its oncology work, is re‑investing in neurological and psychiatric disease programs, a move rooted in assets gained from its 2019 $74 billion Celgene merge…
- Trump announces nine voluntary drug pricing agreements with mid-size biotech firmsOn August 31, 2026, the White House announced that President Donald Trump has secured nine new voluntary drug-pricing agreements with mid-size biotechnology companies. The companies entered the de…